Pacira Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>PP</div>
PCRX -- USA Stock  

USD 63.36  0.92  1.43%

Pacira Pharmaceuticals Receivables Turnover is fairly stable at the moment as compared to the past year. Pacira Pharmaceuticals reported Receivables Turnover of 9.85 in 2019. Inventory Turnover is likely to rise to 2.05 in 2020, whereas Net Income Per Employee is likely to drop (19.6 K) in 2020. The essential goal of this article is to break down our current position on Pacira for investors considering to short it. We will inspect why Pacira Pharmaceuticals investors may still consider a stake in the business.
Published over three weeks ago
View all stories for Pacira Pharmaceuticals | View All Stories
Our current forecast of Pacira (NASDAQ:PCRX)
Pacira Pharmaceuticals is UNDERVALUED at 56.03 per share with modest projections ahead. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pacira Pharmaceuticals has an asset utilization ratio of 105.3 percent. This suggests that the company is making $1.05 for each dollar of assets. An increasing asset utilization means that Pacira Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Pacira Pharmaceuticals. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Pacira Pharmaceuticals


How important is Pacira Pharmaceuticals's Liquidity

Pacira Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Pacira Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Pacira Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Pacira Pharmaceuticals's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Pacira Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Max Reinhardt of 25000 shares of Pacira Pharmaceuticals subject to Rule 16b-3

Legal trades by Pacira Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pacira insider trading alert for exercise of stock option (right to buy) by Max Reinhardt, President, on 17th of November 2020. This event was filed by Pacira Biosciences Inc with SEC on 2020-11-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Pacira Pharmaceuticals exhibits very low volatility with skewness of 0.02 and kurtosis of -0.38. However, we advise investors to further study Pacira Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Returns Breakdown

Return on Investment1.67
Return on Assets(1.56)
Return on Equity(3.51)
Return Capital0.0184
Return on Sales0.0335

Is Pacira showing appearance of lower volatility?

Value At Risk just dropped to -3.21, may suggest upcoming price decrease. Pacira Pharmaceuticals exhibits very low volatility with skewness of 0.02 and kurtosis of -0.38. However, we advise investors to further study Pacira Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Pacira Pharmaceuticals

While some other companies in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Pacira may not be as strong as the others in terms of longer-term growth potentials. In closing, as of the 29th of October 2020, our analysis shows that Pacira Pharmaceuticals moves indifferently to market moves. The company is undervalued and projects below average probability of financial unrest for the next 2 years. Our latest 30 days advice on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Pacira Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com